Gilead Sciences, Inc.
GILD
$134.94
$1.421.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.48% | 2.39% | 2.78% | 3.81% | 4.68% |
| Total Other Revenue | 100.00% | 100.00% | 0.00% | 0.00% | -- |
| Total Revenue | 3.48% | 2.40% | 2.78% | 3.81% | 4.69% |
| Cost of Revenue | -1.67% | -0.34% | -0.63% | -0.40% | 1.96% |
| Gross Profit | 4.91% | 3.16% | 3.75% | 5.02% | 5.47% |
| SG&A Expenses | 0.87% | -4.88% | 1.26% | 4.00% | -4.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.18% | -2.44% | 0.65% | 1.47% | -1.22% |
| Operating Income | 9.43% | 10.57% | 6.30% | 7.83% | 15.93% |
| Income Before Tax | 57.17% | 1,317.66% | 5,485.31% | 367.90% | 534.88% |
| Income Tax Expenses | 75.70% | 509.48% | 2,719.05% | 75.89% | 39.38% |
| Earnings from Continuing Operations | 54.50% | 1,672.92% | 7,014.04% | 510.94% | 1,202.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.50% | 1,672.92% | 6,336.51% | 499.34% | 1,132.44% |
| EBIT | 9.43% | 10.57% | 6.30% | 7.83% | 15.93% |
| EBITDA | 7.38% | 8.34% | 5.04% | 6.28% | 12.59% |
| EPS Basic | 55.01% | 1,682.86% | 6,407.19% | 501.26% | 1,144.01% |
| Normalized Basic EPS | 10.89% | 11.73% | 6.74% | 7.33% | 14.97% |
| EPS Diluted | 54.86% | 1,807.24% | 8,473.77% | 522.15% | 1,273.20% |
| Normalized Diluted EPS | 10.68% | 11.24% | 6.21% | 6.94% | 14.78% |
| Average Basic Shares Outstanding | -0.32% | -0.26% | -0.14% | -0.08% | -0.08% |
| Average Diluted Shares Outstanding | -0.14% | 0.20% | 0.38% | 0.32% | 0.10% |
| Dividend Per Share | 2.90% | 2.60% | 2.61% | 2.63% | 2.65% |
| Payout Ratio | -0.34% | -0.94% | -0.98% | -0.83% | -0.92% |